Rigel Pharmaceuticals, Inc. announced no overall differences in effectiveness were observed between patients 65 years and older and younger patients. Compared to patients younger than 65 years of age, an increase in incidence of hepatotoxicity and hypertension was observed in patients =65 years of age. HEPATIC IMPAIRMENT In patients with mild or moderate hepatic impairment, closely monitor for increased probability of differentiation syndrome.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 USD | +2.79% | -11.30% | -29.66% |
07/05 | Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
07/05 | Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.66% | 179M | |
+2.97% | 108B | |
+10.21% | 104B | |
+2.50% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- RIGL Stock
- News Rigel Pharmaceuticals, Inc.
- Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics